Running Point Capital Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Running Point Capital Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400	Closed	-$2K	–	242
2022 Q2	$2K	Hold	400	–	–	﹤0.01%	225
2022 Q1	$4K	Buy	+400	New	+$4.86K	﹤0.01%	214

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Running Point Capital Advisors's NBRV Position: Q3 2022 in Review

Running Point Capital Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2022, closing a stake of 400 shares — an estimated $2K sold.

Running Point Capital Advisors first reported a position in NBRV in Q1 2022 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 13 funds tracked by Wall St. Rank hold NBRV as of Q3 2022.

Running Point Capital Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2022 after selling out during the quarter.
Running Point Capital Advisors sold 400 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2022, an estimated $2K.
Running Point Capital Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2022 and held it in 2 quarters.
Running Point Capital Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $4K in Q1 2022.
13 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2022.

Based on Running Point Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.